(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine CAS 1234356-69

Product Description:

Product Name:

(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine CAS NO: 1234356-69-4

Synonyms:

Derazantinib;

Derazantinib (ARQ-087);

ARQ-087;ARQ087;

Chemical & Physical Properties:

Appearance: Solid or powder

Assay :≥98.0%

Density: 1.218±0.06 g/cm3(Predicted)

Boiling Point: 615.1±65.0℃(Predicted)

PKa: 9.04±0.19(Predicted)

Flash Point: 325.8±34.3℃

Vapor Pressure: 0.0±1.8 mmHg at 25℃

Index of Refraction: 1.632

Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation of key cellular behaviors including proliferation, cell differentiation and so on. FGFR dysregulation is considered as a driver in multiple cancers. ARQ 087 binds to FGFR and effectively inhibits the activation of FGFR thus can suppress tumorigenesis and tumor growth.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.